Navigation Links
Due to Rising Costs of Asthma and Chronic Obstructive Pulmonary Disease Drugs, Managed Care Organization Pharmacy Directors Will be Forced to Tighten Their Formularies

NASHVILLE, Tenn. and GLEN ROCK, N.J., Oct. 6 /PRNewswire/ -- HealthLeaders-InterStudy and Fingertip Formulary find that due to the rising costs of asthma and chronic obstructive pulmonary disease (COPD) drugs, managed care organization pharmacy directors will tighten their formularies. According to the report entitled Formulary Advantages in Asthma and COPD, the majority of surveyed pharmacy directors expect asthma and COPD drug prices to increase over the next five years by an average of three percent annually and believe they can implement tightened formulary strategies to slow down this trend.

The arrival of generics and branded generics may lead managed care organizations to include only the highest-rebating therapy on Tier 2 and shift other medications within a drug class to Tier 3 or exclude them from their formulary altogether. Novel branded long-acting beta-2 agonists and inhaled corticosteroid (LABA/ICS) combination therapies are expected to launch in 2013-2014 and will generate enough competition to spur the use of higher rebates for tier placement.

"As the price for asthma and COPD drugs increases and competition among therapies grows, more plans will consider tightened formularies and formulary exclusion," said HealthLeaders-InterStudy Analyst Roy Moore, author of the report. "Medicare plans are taking the lead with tighter formularies. Pharmaceutical companies will have to consider using rebates to ensure preferred formulary status for asthma and COPD drugs on most health plans."

The new Formulary Forum report is based on a survey of 47 U.S. pharmacy directors who control formularies at national, regional and state-level managed care organizations, as well as historical formulary data from Fingertip Formulary.

About Fingertip FormularyFingertip Formulary (, the leading provider of access to and insight into formulary data in the United States, offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others. Fingertip Formulary is a Decision Resources, Inc. company.

About HealthLeaders-InterStudyHealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Erin O'Leary

Elizabeth MarshallHealthLeaders-InterStudy

Decision Resources, Inc. 781-993-2641

SOURCE HealthLeaders-InterStudy
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Analysis Shows Troubling Trend in Triglyceride Levels May Be Linked to Rising Rates of Obesity
2. Pharmaceutical and Life Sciences Companies Face Rising Tax Rates, Says PricewaterhouseCoopers
3. Top 5 Global Spinal Implant Companies Maintaining Position but Competition Rising Rapidly
4. Roches Quinn Honored as 2010 HBA Rising Star
5. Rising Burden of Diseases Drives the Pharmaceutical Industry in East Africa, Says Frost & Sullivan
6. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
7. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
8. Study Says Allergy Shots Help Children, Reduce Health Care Costs
9. Drug Combo Could Lower Diabetes Complications and Costs
10. DaVita Strives to Improve Quality of Life and Reduce Overall Costs of Kidney Care Through Community-Based Education
11. Complications and Costs for Obesity Surgery Declining
Post Your Comments:
(Date:10/12/2015)... New York , October 12, 2015 ... (FMI) delivers key insights on the global vital signs monitoring ... Devices Market: Global Industry Analysis and Opportunity Assessment 2015-2025." The ... at a healthy CAGR of 9.5% and 9.2% in terms ... to factors, regarding which FMI offers major insights in detail ...
(Date:10/12/2015)... Oct. 12, 2015 Beginning October 1, 2015 ... Partner, the fastest growing practice management system for therapists, ... easily converts all patient diagnostic codes from the former ... --> --> Therapy Partner has ... mental health practitioners to easily understand the conversion to ...
(Date:10/12/2015)... , Oct. 12, 2015 Indivior PLC (LON: INDV) ... of Delaware granted the Company,s motion ... Abbreviated New Drug Application (ANDA) No. 205299 to market a ... and naloxone) Sublingual Film (CIII) in the United ... Since August 2013, Indivior has received Paragraph IV certifications ...
Breaking Medicine Technology:
(Date:10/12/2015)... ... October 12, 2015 , ... To help ... its charitable donation to the National Breast Cancer Foundation. The National Breast Cancer ... breast cancer through early detection, education, and support services. , The annual campaign ...
(Date:10/12/2015)... ... October 12, 2015 , ... SQM Group ... a contact channel benchmarking study. Be a part of this insightful ... for improving customer experience, customer journey, contact channel execution and intelligence, workforce optimization, ...
(Date:10/12/2015)... ... ... Holcomb – Kreithen Plastic Surgery and MedSpa, PLLC (“Holcomb – Kreithen”), one of ... Surgery University,” an educational series of mini seminars covering aesthetic and plastic surgery options, ... Saturday, October 24, 2015. , The goal of the event is to provide hands-on ...
(Date:10/12/2015)... ... October 12, 2015 , ... The Asthma and ... Engagement Award by the Patient-Centered Outcomes Research Institute (PCORI) for a new project ... , The project, entitled “Training Patients with Asthma to Understand and Participate in ...
(Date:10/12/2015)... ... October 12, 2015 , ... International law firm Greenberg ... with the U.S. Biomedical Advanced Research and Development Authority (BARDA) reported to be ... ReCell® Autologous Cell Harvesting Device under a U.S. mass casualty preparedness program. ...
Breaking Medicine News(10 mins):